REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2025 November 13, 2025 All economic indicators have substantially improved: Consolidated turnover of €1,819.8 million (1,669.6 as at 30 September 2024) EBITDA of €335.5 million (275.5 as at 30 September 2024) EBIT of €281.0 million (224.2 as at 30 September 2024) Pre-tax profit of €268.1 million (216.0 as at 30 September 2024) Positive Net Financial Position of €423.1 million.
Almirall’s 2025 9M Results November 10, 2025 Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress Sustained strong growth momentum with 12.8% Net Sales YoY increase to a total of €820.7 MM, with biologics continuing to deliver double-digit growth YoY and dermatology sales in Europe increasing 24.5% YoY further advancing Almirall´s leadership in medical dermatology. EBITDA increase of 27.1% YoY in line with expectations, reaching a total of €180.7 MM. On track to meet 2025 guidance driven by biologics growth and operational strength. Performance continues to be primarily driven by the biologics portfolio, with Ilumetri® net sales increasing 12.1% YoY (total of €170.9 MM), and Ebglyss® net sales of €75.5 MM – reflecting a more than 3x increase YoY as European markets are ramping up after launch. Solid performance of the broad dermatology product portfolio with Wynzora® growing 32.4% YoY to a total of €25.4 MM, and Klisyri® growing 22.6% YoY to a total of €20.1 MM, further enhancing Almirall’s position as trusted partner for patients and dermatologists. Continued R&D pipeline progress includes the start of the phase II study of the anti-IL-1RAP mAb, and plan to initiate three additional proof-of-concept studies over the coming 9 to 12 months.
TITAN Group: Nine-Month 2025 Results November 6, 2025 Regulatory News: Titan SA (Euronext Brussels, ATHEX and Euronext Paris, TITC) announces the nine-month 2025 financial results. Record nine-month EBITDA profitability and a positive outlook Group Sales YTD increased by 1.4%, at €2,013m, thanks to the strong performance in Greece, in the US & in Egypt, driven by increased volumes and overall firm pricing levels. [...]